Kintara Therapeutics Inc (NASDAQ:KTRA) CEO Saiid Zarrabian tells Proactive the biotechnology group closed its fiscal third quarter with cash and cash equivalents of about $15.7 million, which is expected to be sufficient to fund its planned operations to the second quarter of calendar year 2022.
Zarrabian says Kintara achieved the healthy cash runway primarily due to prudent cash management as well as the exercise of previously issued warrants. Zarrabian also updated investors on the group's ongoing clinical trials including its AGILE study to treat brain cancer.